

Reply letter

Carmen Baccharini,^{1,*} Andrew Ternouth,² Heather Wieffer² and Andrew Vyse³

¹GlaxoSmithKline Vaccines; King of Prussia, PA USA; ²Heron Evidence Development Ltd; Luton, UK; ³GlaxoSmithKline Vaccines; Wavre, Belgium

Keywords: Literature review, *Neisseria meningitidis*, North America, epidemiology, meningococcal disease

Dear Editors,

We thank Dr Bettinger et al¹ for the clarification, and for providing valuable updates on the current epidemiology and surveillance of meningococcal disease in Canada. The objective of our review was to provide an overview of the epidemiology of meningococcal disease in North America during the last half century and portray how it has evolved over time, particularly in response to the different vaccination strategies employed by the US and Canada, rather than focus on the contemporary situation in each country.

Reference

1. Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Le Saux N. Response to the changing epidemiology of meningococcal disease in North America 1945–2010. *Hum Vaccin Immunother* 2013; 9:1323 - 1324; PMID: 23454840; <http://dx.doi.org/10.4161/hv.24009>

*Correspondence to: Carmen Baccharini; carmen.i.baccharini@gsk.com

Submitted: 02/15/13; Accepted: 02/23/13

<http://dx.doi.org/10.4161/hv.24087>

Reply to: Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Le Saux N. Response to the changing epidemiology of meningococcal disease in North America 1945–2010. *Human Vaccines & Immunotherapeutics* 2013; 9:1323 - 1324; PMID: 23454840; <http://dx.doi.org/10.4161/hv.24009>